M. Petrie

发表

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Michael Wall, J. Herbert, Jack H. Simon, 2002, Neurology.

Cortical motor reorganization after paraplegia

S. Pandya, M. Mcdermott, A. Goodman, 1999, Neurology.

Multiple sclerosis. Sexual dysfunction and its response to medications.

D. Mattson, M. Mcdermott, M. Petrie, 1995, Archives of neurology.

The measurement of ambulatory impairment in multiple sclerosis

D. Mattson, M. Mcdermott, J. Dudman, 1997, Neurology.

Quantitative assessment of sustained‐release 4‐aminopyridine for symptomatic treatment of multiple sclerosis

M. Mcdermott, A. Goodman, D. Mason, 1997, Neurology.

A randomized controlled study of the acute and chronic effects of cooling therapy for MS

Hank C. Lee, L. Montgomery, R. Guisado, 2003, Neurology.

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

Michael Wall, D. Barlett, J. Herbert, 2002, Multiple sclerosis.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

J. Wolinsky, H. Panitch, C. Ford, 2006, Multiple sclerosis.

Conditioning of cyclophosphamide-induced leukopenia in humans.

R. Ader, R. Schiffer, D. Mattson, 1996, The Journal of neuropsychiatry and clinical neurosciences.

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

J S Wolinsky, J. Wolinsky, P. Narayana, 2001, Multiple sclerosis.